1. Home
  2. SWMR vs CHRS Comparison

SWMR vs CHRS Comparison

Compare SWMR & CHRS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

SWMR

Swarmer Inc Common Stock

N/A

Current Price

$41.74

Market Cap

338.8M

Sector

Technology

ML Signal

N/A

Logo Coherus BioSciences Inc.

CHRS

Coherus BioSciences Inc.

HOLD

Current Price

$1.34

Market Cap

296.8M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
SWMR
CHRS
Founded
2023
2010
Country
United States
United States
Employees
N/A
N/A
Industry
Computer Software: Prepackaged Software
Biotechnology: Biological Products (No Diagnostic Substances)
Sector
Technology
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
338.8M
296.8M
IPO Year
2026
2014

Fundamental Metrics

Financial Performance
Metric
SWMR
CHRS
Price
$41.74
$1.34
Analyst Decision
Strong Buy
Analyst Count
0
4
Target Price
N/A
$5.51
AVG Volume (30 Days)
735.7K
917.9K
Earning Date
05-20-2026
05-07-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
472.00
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
$2,862.05
$73.08
Revenue Next Year
$177.93
$30.94
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$25.75
$0.72
52 Week High
$83.30
$2.62

Technical Indicators

Market Signals
Indicator
SWMR
CHRS
Relative Strength Index (RSI) 44.38 34.81
Support Level $30.45 $1.27
Resistance Level $68.97 $1.42
Average True Range (ATR) 10.88 0.08
MACD -2.64 -0.01
Stochastic Oscillator 4.75 1.45

Price Performance

Historical Comparison
SWMR
CHRS

About SWMR Swarmer Inc Common Stock

Swarmer Inc is a provider of autonomous drone swarm software and AI solutions, specializing in vendor-agnostic technologies. It develops software platforms and artificial intelligence systems for defence applications, enabling military organisations to deploy and coordinate large-scale unmanned and autonomous systems. Its offerings include swarm coordination software, multi-domain unmanned systems integration, collaborative autonomy solutions, and command-and-control software for distributed robotic operations. Its key software and AI systems include: i) STYX AI Command & Control System, ii) MINAS Autonomy and Collaboration AI and iii) TRIDENT Embedded Drone Operating System. The company generates revenue through software license sales.

About CHRS Coherus BioSciences Inc.

Coherus Oncology Inc is a fully integrated commercial-stage inventive oncology company with an approved next-generation PD-1 inhibitor, LOQTORZI, and a pipeline that includes two mid-stage clinical candidates targeting liver, lung, head & neck, and other cancers. Its portfolio includes LOQTORZI which was developed for its ability to block PD-1 interactions with its ligands, PD-L1 and PD-L2, by binding to the FG loop on the PD-1 receptor. Company believe blocking PD-1 interactions with PD-L1 and PD-L2 can help to promote the immune systems.

Share on Social Networks: